Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 15, Issue 12, Pages 748-762Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41571-018-0111-2
Keywords
-
Categories
Funding
- Philanthropia Fondation
Ask authors/readers for more resources
Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall survival of a subset of patients across multiple solid tumour types, but other patients can have a deterioration of their disease as a result of such therapies. This paradoxical phenomenon is defined as hyperprogression. In this Review, we present the available evidence of hyperprogressive disease following immune-checkpoint inhibition, the pathophysiological hypotheses that might explain hyperprogressive disease and the current challenges for patient management in routine clinical settings. Finally, we also discuss how the risk of hyperprogressive disease should be taken into account in clinical decisions involving immune-checkpoint inhibition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available